drugset / Trial / NCT06242652

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

NCT06242652

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the effect and safety of 608 in patients with AS.

Timeline

Start
2024-03-19
Primary completion
2025-02-27
Completion
2025-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 608 Unknown Subcutaneous
Comparator Adalimumab Monoclonal antibody Subcutaneous